10795--11/30/2006--BECTON_DICKINSON_&_CO

related topics
{regulation, government, change}
{product, liability, claim}
{operation, international, foreign}
{operation, natural, condition}
{customer, product, revenue}
{acquisition, growth, future}
{property, intellectual, protect}
{financial, litigation, operation}
{product, market, service}
BD s future growth is dependent upon the development of new products, and there can be no assurance that such products will be developed. The medical device industry is very competitive. A reduction or interruption in the supply of certain raw materials would adversely affect BD s manufacturing operations and related product sales. Interruption of our manufacturing operations could adversely affect BD s future revenues and operating income. BD is subject to a number of pending lawsuits Consolidation in the healthcare industry could adversely affect BD s future revenues and operating income. Changes in reimbursement practices of third-party payers could affect the demand for our products and the prices at which they are sold. Product defects could adversely affect the results of our operations. BD is subject to extensive regulation. We cannot guarantee that any of BD s strategic acquisitions, investments or alliances will be successful. We are subject to foreign currency exchange risk. The international operations of BD s business may subject BD to certain business risks. Reductions in customers research budgets or government funding may adversely affect our BD Biosciences segment. Our operations are dependent in part on patents and other intellectual property rights. Natural disasters, war or terrorism could adversely affect BD s future revenues and operating income.

Full 10-K form ▸

related documents
10795--11/23/2007--BECTON_DICKINSON_&_CO
10795--11/26/2008--BECTON_DICKINSON_&_CO
10795--11/25/2009--BECTON_DICKINSON_&_CO
313143--5/27/2008--HAEMONETICS_CORP
10795--11/24/2010--BECTON_DICKINSON_&_CO
1000736--3/2/2006--CAREMARK_RX_INC
874716--2/19/2010--IDEXX_LABORATORIES_INC_/DE
313143--5/25/2007--HAEMONETICS_CORP
780127--1/5/2010--SYNOVIS_LIFE_TECHNOLOGIES__INC
1136869--2/28/2007--ZIMMER_HOLDINGS_INC
40533--2/22/2008--GENERAL_DYNAMICS_CORP
874716--2/20/2009--IDEXX_LABORATORIES_INC_/DE
856982--3/10/2010--MERIT_MEDICAL_SYSTEMS_INC
862668--9/29/2008--ESCALON_MEDICAL_CORP
33113--5/12/2009--ENVIRONMENTAL_TECTONICS_CORP
1099800--2/26/2010--Edwards_Lifesciences_Corp
913165--3/16/2007--EXACTECH_INC
203077--3/2/2010--ST_JUDE_MEDICAL_INC
862668--10/12/2010--ESCALON_MEDICAL_CORP
1099800--3/2/2009--Edwards_Lifesciences_Corp
949874--3/14/2008--YOUNG_INNOVATIONS_INC
949874--3/15/2007--YOUNG_INNOVATIONS_INC
799729--9/8/2006--PAREXEL_INTERNATIONAL_CORP
949874--3/12/2009--YOUNG_INNOVATIONS_INC
1163848--3/7/2007--INTRALASE_CORP
1163848--3/3/2006--INTRALASE_CORP
742112--2/27/2009--INVACARE_CORP
880432--9/28/2009--MISONIX_INC
739708--3/1/2007--CLEAR_CHANNEL_COMMUNICATIONS_INC
739944--3/10/2009--MEDTOX_SCIENTIFIC_INC